ARHGDIB and neoplasm: RhoGDI2 was found to be significantly upregulated in tumour samples from patients with pancreatic adenocarcinoma (PDAC) wherein its expression positively correlated with tumour size, differentiation, clinical stage, lymph node metastasis, vascular invasion and reduced life expectancy (see Figure 5).